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Abstract
Aims: To investigate the impact of iron intake on the development of type 1 diabetes (T1DM).
Methods: Case-control study with self-administered questionnaire among families of children with T1DM who
were less than 10 years old at the time of the survey and developed diabetes between age 1 and 6 years. Data on
the types of infant feeding in the first 4 months of life was collected from parents of children with T1DM (n = 128)
and controls (n = 67) <10 years old. Because some cases had sibling controls, we used conditional logistic
regression models to analyze the data in two ways. First we performed a case-control analysis of all 128 cases and
67 controls. Next, we performed a case-control analysis restricted to cases (n = 59) that had a sibling without
diabetes (n = 59). Total iron intake was modeled as one standard deviation (SD) increase in iron intake. The SD for
iron intake was 540 mg in the total sample and 539 mg in the restricted sample as defined above.
Results: The median (min, max) total iron intake in the first 4 months of life was 1159 (50, 2399) mg in T1DM
cases and 466 (50, 1224) mg among controls (P < 0.001). For each one standard deviation increase in iron intake,
the odds ratio (95% confidence interval) for type 1 diabetes was 2.01 (1.183, 3.41) among all participants (128 cases
and 67 controls) while it was 2.26 (1.27, 4.03) in a restricted sample of T1 D cases with a control sibling (59 cases
and 59 controls) in models adjusted for birth weight, age at the time of the survey, and birth order.
Conclusion: In this pilot study, high iron intake in the first 4 months of infancy is associated with T1DM. Whether
iron intake is causal or a marker of another risk factor warrants further investigation.
Background
The incidence of type 1 diabet e s( T 1 D M )i si n c r e a s i n g
worldwide and the age of onset is shifting downwards with
a significant number of cases occurring between birth and
4 years of age [1-4]. Although the causes for increased
incidence and early onset of T1DM are uncertain [1], a
number of risk factors associated with induction of auto-
immunity in the genetically susceptible individuals have
been suggested. These include viral infections (especially
enterovirus), stressful life events, vaccinations, early expo-
sure to milk protein, such as bovine insulin, casein and
other proteins, early introduction of cereal to infants, low
serum vitamin D levels and premature exposure of the gut
immune system to foreign proteins [5-19]. The role of
environmental determinants in initiating the autoimmu-
nity cascade has also been suggested by studies in discor-
dant/concordant twins [20,21]. Prolonged breast feeding
may protect against type 1 diabetes [22,23]. Timing of
introduction of solids/cereals was found to influence the
risk of developing islet autoimmunity whereas breastfeed-
ing duration/introduction of cow’s milk were not statisti-
cally associated with the risk factor for developing islet
auto antibodies [11,24]. There are no major associations
reported between breast feeding and risk of T1DM
[11,25,26].
Iron, a major supplement in fortified baby formula,
could play a role in modifying the risk for T1DM given
t h a ts t u d i e si na d u l t sh a v es uggested an association
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months of life, there is an increased breakdown of fetal
erythrocytes leading to increased amounts of circulating
iron that are subsequently stored in the parenchymal
cells of liver and reticuloendothelial macrophages
[27,28]. The estimated iron requirement for the term
infant for the expansion of the erythrocyte mass and to
maintain adequate stores is 1 mg/kg/day [27,29]. Iron
absorption for term infants fed cow’s milk formulas var-
ies from 4-12% depending on a variety of factors includ-
ing age of the infant, reticulocyte count, body iron
status, and composition of the baby formula (e.g.,
calcium concentration and added ascorbic acid).
Absorption levels are even lower with soy milk formula.
Studies using isotopically labeled iron reveal that the
bioavailability of iron in infant formulas is approximately
11% [30] and 11.3% in premature and term babies,
respectively [31]. Compared to breast milk, from which
approximately 50% of the iron is absorbed [27,31,32],
only about 19% of the iron in baby formula is absorbed
[33]. In vivo, recombinant human lactoferrin added to
the infant formula attenuated iron mediated free radical
formation and lipid peroxidation [34]. Thus, lack of
breast milk lactoferrin may predispose the formula fed
infants for further added oxidative damage at critical
time period.
The American Academy of Pediatrics Committee on
Nutrition recommends early use of iron-fortified for-
mula instead of cow milk [27]. This has reduced the
prevalence of anemia in children ages from 6 months to
60 months[35]. Since 1974, the Special Supplemental
Nutrition Program for Women, Infants and Children
(WIC) provides only high iron formula, unless there are
special instructions against this by a health care provi-
der. In 2001 the National Academy of Sciences recom-
mended that the Dietary Reference Intake of iron (DRI)
in infants 0-6 months to be 0.27 mg/day with a tolerable
upper intake level of 40 mg/day with an assumption that
75% of iron is from heme iron sources [36]. Mature
human breast milk contains 0.5 mg/L of iron [35], a
considerably lower concentration of iron than iron-forti-
fied baby formulas which also vary in the type and
source of protein (e.g., bovine, soy or protein hydroly-
sate). The aim of this study is to explore whether the
amount of iron consumed in the first 4 months of life is
associated with T1DM before 6 years of age. A 6 year
age cut off was used mainly because children are
exposed to more environmental stimuli after that age.
Even though a cause-effect relationship cannot be vali-
dated with this study, we aimed to assess a potential
association between iron consumption in the first 4
months of life and risk of developing T1DM as a preli-
minary step for future studies.
Materials and methods
Subjects
This was a case-control study among children diag-
nosed with T1DM before the age of six and who at the
time of recruitment were not older than 10 years and
were receiving care from the pediatric diabetes clinic
at the Birmingham Children’s Hospital, a University of
Alabama at Birmingham (UAB) affiliated hospital.
Patients were identified through the Children’sH o s p i -
tal electronic medical records system using ICD 9
diagnosis codes 250.01, 250.03 and 250.13. Surveys
were sent to a total of 250 children diagnosed with
T1DM before 6 years of age and at the time of survey
not >10 years old. A total of 141 surveys from children
with T1DM were returned of which 130 children with
diabetes were entered in the analysis and 11 excluded
because of unclear answers. Some (n = 75) of the con-
trol questionnaires were rejected due to ambiguity in
the answers leaving 83 controls eligible for further ana-
lysis. Thus our main sample consisted of a total of 130
T1DM cases and 83 controls which includes siblings of
T1DM cases. Since type 1 diabetes is characterized by
significant insulinopenia which requires insulin admin-
istration to control blood sugar, the controls were
selected based on parents history of whether or not
the sibling had diabetes. Siblings of T1DM children
were included in the study if they were aged between
6 years and 10 years of age.
Methods
After obtaining approval by the University of Alabama
at Birmingham Institutional Review Board, 250 ques-
tionnaire surveys were mailed out between June 2006
and April 2007. Data collection: A questionnaire and let-
ter of introduction stating that this research is being
conducted to determine whether maternal nutrition,
childhood infections, co-morbidities and the type and
components of infant formula (e.g., minerals and vita-
mins) are associated with T1DM were mailed to the
parents or guardians of the study participants. A ques-
tionnaire, which was completed by the parent or care-
taker, was used to assess maternal medical history and
baby feeding practices (e.g., gestational diabetes, mater-
nal T1DM or type 2 diabetes (T2DM), period of exclu-
sive breast feeding, introduction of supplementary infant
formula, type of formula consumed in the first 4 months
of life, number of weeks on formula, and vitamins and
iron supplements) as well as child specific information
such as birth weight, year of birth and illnesses in the
first 4 months of life. The names of the patients and
their caregivers were not included on the survey form.
Anonymous filled questionnaires were returned to the
Children’s Hospital in self-addressed stamped return
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provided by the researchers.
Assessment of amount and duration of intake of specific
iron containing foods
The infant formulas were then classified as high or low
iron formula based on the self-reported formula brand
name. The majority of available products at the time of
the study were high iron except Similac low iron®, Simi-
lac PM 60/40® and Enfamil Lipil low iron® infant formu-
las. Comparisons were made between children with
T1DM and non-diabetic siblings based on consumption
of high-iron, low-iron formulas and breast milk.
If a survey was marked as formula fed for a month, we
used a 30 day month. Calculation of total amount of
formula ingested was based on normal caloric needs
of food intake for infants [37]. Breast milk has 0.5 mg/L
of iron, equivalent to 0.075 mg in 5 oz [35]. “High” iron
formula has 12 mg/L (1.8 mg/5 oz) of iron and “low”
iron formula has 4.6 mg/L (0.7 mg/5oz) of formula of
ferrous iron. Table 1 depicts the expected amount of
iron ingested based on the recommended daily intake of
formula or breast milk in the first 4 months of life.
Inclusion and exclusion criteria
We excluded individuals where the parent could not
recall the type of infant nutrition source and whether or
not solid foods (e.g., cereals) were introduced before 4
months of age, if there were serious illnesses prior to
the diagnosis of diabetes (to exclude medication-induced
diabetes), if gestational length was ≤ 37 weeks) and if
diabetes was diagnosed after 6 years of age. Siblings
were excluded from the study if they were >10 years at
the study point for age- matching with the cases.
Statistical analyses
Data management and analysis was done in Microsoft
EXCEL® and Statistical Analysis System (SAS version
9.2, SAS Institute Inc., Cary, NC). From total sample of
213, we excluded individuals who had missing data on
age (n = 16), sibling rank (n = 1) and one child who
iron intake was implausible (11,988 mg). Thus we had
195 children (67 controls and 128 cases) for the main
analyses. For subgroup analyses, we created a subset of
59 controls and 59 cases where case had a control
sibling. The distribution of iron intake and other contin-
uous variables was checked for normality and log- or
square root-transformed where appropriate to improve
normality before comparing cases and controls. Because
transformations did not completely correct the skewed
nature of the data, we used the Wilcoxon Rank Sum
test to test for the significance of differences in iron
intake as well in other variables between cases and con-
trols. Multivariable conditional logistic regression was
performed to test whether the intake of iron is asso-
ciated with T1DM before and after adjusting for birth
weight, age at the time of the survey and birth order. In
the final sample, there were two few mother’sw i t ha
history of gestational diabetes or T2DM (< 4%). Thus
these variables were not included in the multivariate
conditional logistic analyses. The results are reported as
odds ratios (OR) and 95% confidence intervals (CI) for
1 SD increase in iron intake for all sources. Associations
were considered significant at a P-value of 0.05.
Results
The mean (± SD) age at the time of diagnosis of T1DM
was 3.23 ± 1.32 years. All study participants were born
between 1996 and 2006. The general characteristics of
the study population by case-control status are shown in
Table 2. There was no association between sibling rank
and T1DM, nor was there an association between
maternal history of gestational diabetes or T2 D and
T1DM in children.
The median duration of breast feeding was signifi-
cantly higher (P < 0.05) in controls (12 weeks) than in
T1DM cases (4 weeks). The median (min, max) total
iron intake in the first 4 months of life was 1159 (50,
2399) mg in T1DM cases and 466 (50, 1224) mg among
controls (P < 0.001). The SD for iron intake was 540 mg
in the total sample and 539 mg in the restricted sample.
Table 3 depicts odds ratios for the association between
Table 1 The amount of iron intake that a normal term infant receiving the recommend daily allowance (RDA) of
formula or breast milk would receive in the United States*
Month RDA milk
(oz/day)
Iron, mg/day Vitamin with iron (10 mg/serving)
High-iron formula Low-iron
formula
Breast milk
First month 23 8.28 3.22 0.345 300
Second month 29 10.44 4.06 0.435 300
Third month 29 10.44 4.06 0.435 300
Fourth month 30 10.8 4.2 0.45 300
* Breast milk has 0.5 mg/L of iron, equivalent to 0.074 mg in 5 oz [35]. High iron formula has 1.8 mg/5 oz of formula and low iron formula has 0.7 mg/5 oz of
formula.
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first four months of life and type 1 diabetes. For each
one standard deviation increase in iron intake, the odds
ratio (95% confidence interval) for type 1 diabetes was
2.01 (1.183, 3.41) among all participants (128 cases and
67 controls) while it was 2.26 (1.27, 4.03) in a restricted
sample of T1 D cases with a control sibling (59 cases
and 59 controls) in models adjusted for birth weight,
age at the time of the survey and birth order. In multi-
variate analyses, only age at the recruitment was asso-
ciated with T1DM. For each one year increase in age,
the odds ratio for T1DM was 1.44 (1.07, 1.95) in models
adjusted for total iron intake, birth weight and sibling
rank.
Discussion
The novel proposition of a causal link between the
quantity of iron intake in the first 4 months of life and
future development of T1DM is plausible considering
the known strong association between ferritin and Type
2 diabetes in adults [38,39], a disorder sometimes diag-
nostically indistinct from T1DM with similar surrogate
autoimmune markers and medical histories. Because in
genetically susceptible subjects b-cell auto antibodies
may materialize in infancy [40], this observation but-
tresses the argument that the environmental trigger for
diabetes autoimmunity occurs early in life.
The physiological anemia of infancy seen in the first
2-3 months of life is not due to iron deficiency and does
not respond to iron supplementation [35]. A normal
term infant has sufficient iron stores for the first 4-6
months of life. Hence, the introduction of iron fortified
formula in the critical period of 4-6 months could be
potentially baneful. There has been a significant reduc-
t i o ni nt h ep r e v a l e n c eo fi r o nd e f i c i e n c ya n e m i ai n6t o
60 month-old children after the introduction of iron-
fortified baby formulas. However, there is limited clinical
evidence which can be adduced to support the early
Table 2 characteristics of the study participants by diabetes status*
Controls
(n = 67)
Type 1 diabetes cases
(n = 128)
Variable Median Min, Max Median Min, Max P
Age at diagnosis, y ––3.0 0.16, 6.0 –
Age at recruitment, y 5.0 0.4,10.0 6.0 2.0, 10.0 0.05
Birth weight, kg 3.32 2.3, 4.7 3.32 1.11, 4.91 0.94
Total iron: form., suppl. & breast milk, mg 466 50, 1224 1159 50, 2399 < 0.0001
Iron from formula & supplements, mg 466 0, 1213 1144 0, 2399 < 0.0001
Duration of feeding low-iron formula, wks 12 0, 16 0 0, 16 < 0.0001
Duration of feeding high-iron formula, wks 12 0, 32 10 0, 16 0.10
Duration of breast feeding, wks 12 0, 16 4 0, 16 0.001
Mother had gestational diabetes, % 0 3 0.30
Mother has diabetes, % 3 4 1.00
Sibling rank, %
First 42 49 0.44
Second 49 42
Third 6 8
Forth or higher 3 1
* Values are medians, minimum, maximum or percentages.
†P values are from the Wilcoxon rank sum test for continuous variables and from the Fisher’s exact test for categorical variables.
Table 3 Odds ratios (95% CI) for the association between total iron intake in first four months of life and type 1
diabetes
Odds ratios (95% CI) for 1 SD increase in iron intake*
All participants
(128 cases and 67 controls)
Restricted to cases with a control sibling
(59 cases and 59 controls)
Total iron intake, SD units† 2.01 (1.183, 3.41) 2.26 (1.27, 4.03)
Age at recruitment, y 1.44 (1.07, 1.95) 1.69 (1.15, 2.49)
Birth weight, kg 1.09 (0.37, 3.27) 0.77 (0.24, 2.51)
Sibling rank 1.46 (0.62, 3.41) 2.17 (0.77, 6.08)
* Odds ratios are from conditional logistic regression models in which the 4 continuous variables were modeled simultaneously.
† Total iron intake from formula, supplements and breast milk. In the total sample (n = 195) one SD unit was 540 mg while it was 539 mg in the restricted
sample (n = 118).
Ashraf et al. Diabetology & Metabolic Syndrome 2010, 2:58
http://www.dmsjournal.com/content/2/1/58
Page 4 of 7introduction of iron fortified formulas in the first
4 months of life.
Although the mechanism remains unresolved, numer-
ous studies have confirmed that prolonged breast feed-
ing protects against T1DM [23], and breast feeding
activists advocate the postponement of formula feeding.
As regards to iron intake with breast feeding, even
though 50% of the iron is absorbed, which is incontesta-
bly a high proportion when compared with cow’s milk
or iron fortified formula, breast milk per unit volume
contains roughly 1/10
th of the iron content of the “low”
iron formulas [27,32,33,35]. The net result is that breast
fed babies absorb quantitatively far less iron than
formula-fed babies, and this fact alone may explain the
putative effect of breast milk.
Another confounding variable is that breast fed babies
may delay feeding formula, cow’s milk, cereals or other
solid foods. This practice may avert exposure of the
infant to foreign food antigens, such as gluten and
bovine insulin, which may induce a cross-reacting
immune response, particularly if gut permeability is
altered by microbial infection [41]. Contrary to other
studies [35], our study did not show that the number of
weeks of breast milk ingestion conferred protection,
most likely due to the small sample size in our study.
Moreover, only a minority of children were on low-iron
formula and the majority of children who had low total
iron intake in the first 4 months had at some point also
received breast milk. The absence of statistically signifi-
cant association between the number of weeks of breast
milk intake and having diabetes in our study is not
enough to abandon the tenet that breast feeding is a
protective factor against T1DM.
Type 1 diabetes involves the inexorable destruction of
b cells secondary to autoimmunity. In iron overload
conditions such as hemochromatosis, there is excessive
iron storage in solid organs and selective destruction of
b cells. Iron overload form hereditary hemochromatosis
is associated with diabetes and impaired glucose toler-
ance and decreased insulin secretory capacity, which is
reportedly reversed with phlebotomy therapy [42,43].
Excess pancreatic b-cells iron reportedly impairs mito-
chondrial function and glucose-stimulated insulin secre-
tion [43,44].
The etiology of T1DM is likely multifactorial with a
complex interplay between genetic, autoimmune, envir-
onmental, infectious and dietary factors. The role of iron
in the infant formula in manifestation of T1DM was
explored in this study. We could not find any studies
examining relationship of iron status before onset of
T1DM in genetically susceptible individuals. However, as
in other autoimmune disorders, there are reports suggest-
ing iron status may play a role in manifestation of sys-
temic lupus erythematosis in murine models [45]. Iron is
involved in the proliferation of T cells and other cells of
immune system [46]. Similarly, ferritin reportedly has
immune regulatory roles as well [47]. The pathoetiology
by which fortified iron formulas could predispose to
development of autoimmune diabetes in genetically
susceptible individuals is uncertain. Whether the develop-
ment of T1DM appertains to the actual quantity of iron
ingested or is somehow attributable to the type of the
fortified iron (ferrous sulfate vs. ferrous fumarate), or
duration and timing of iron intake is likewise unclear.
Excess cellular uptake of ferrous iron could in theory
initiate a oxidation cascade which overwhelms the
numerous intracellular protective anti-oxidation biochem-
ical strategies [48]. It is thereby conceivable that the oxi-
dative stress from immoderate iron exposure in the first
4 months in genetically susceptible infants may promote
autoimmunity due to overproduction of free radical
oxidative species. Parenthetically, ferrous fumarate is
thought to produce minimal or no oxidative stress in
vitro compared with ferrous sulfate [34]. And, interest-
ingly, lactoferrin in breast milk reportedly attenuates
iron-induced oxidative damage in vitro[34]. Finally, in the
gut an overabundance of iron may modify the gastroin-
testinal immune response or its micronutrient milieu
[49]. In conclusion, large-scale prospective studies are
warranted to determine whether low iron or lactoferrin
enriched formulas forefend against T1DM in high risk
individuals.
Limitations of the study
The major methodological pitfall of this retrospective
study is that the data are self-reported. Hence, there is a
potential chance of error insofar as this information relies
on maternal dietary recall over a long duration. A mem-
ory bias may exist between that of the child with diabetes
and non- diabetic sibling and that could have caused
differential misclassification. Even though the letter
accompanied the survey did not specify our hypothesis
on iron content of formula, it mentioned we are investi-
gating a link between T1DM and any of the minerals,
vitamins, infant formulas or maternal nutrition. As the
surveys were anonymous we do not have any data (clini-
cal, demographic or medical) about the non-responders.
We have excluded all ambiguous surveys. The choice of
infant formula after birth depends on parental prefer-
ences, cost, co-morbid conditions like colic, acid reflux
disease, lactose intolerance, milk protein allergy, type of
formula the mother is first exposed too, etc. Conse-
quently, the choice of low iron formula could be a proxy
for socioeconomic characteristics or other factors which
were not assessed in the surveys. Another confounding
factor is that early introduction of bovine milk formula,
besides increasing iron intake, may introduce previously
proposed diabetogenic protein antigens.
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This pilot study suggests that higher intake of iron in
the first 4 months of life is a probable risk factor for
future development of T1DM. These results are not
conclusive as this study was not designed to assess risk
for T1DM. Even though the association of “high iron
intake” with T1DM is seen in this study, in view of
potential biases that may have confounded the results of
t h i ss t u d y ,af u t u r ep r o s p e c t i v el a r g es c a l es t u d yt o
assess the possible association between high dietary
intake of iron in infancya n dT 1 D Mi sw a r r a n t e d .
W h e t h e ri r o ni n t a k ei sc a u s a lo ram a r k e ro fa n o t h e r
risk factor needs to be further investigated.
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